| Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis M Paul, V Shani, E Muchtar, G Kariv, E Robenshtok, L Leibovici Antimicrobial agents and chemotherapy 54 (11), 4851-4863, 2010 | 832 | 2010 |
| Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy E Muchtar, LA Blauwet, MA Gertz Circulation research 121 (7), 819-837, 2017 | 313 | 2017 |
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 304 | 2017 |
| Systemic amyloidosis from A (AA) to T (ATTR): a review E Muchtar, A Dispenzieri, H Magen, M Grogan, M Mauermann, ... Journal of internal medicine 289 (3), 268-292, 2021 | 215 | 2021 |
| How I treat cryoglobulinemia E Muchtar, H Magen, MA Gertz Blood, The Journal of the American Society of Hematology 129 (3), 289-298, 2017 | 176 | 2017 |
| Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement WI Gonsalves, FK Buadi, S Ailawadhi, PL Bergsagel, AA Chanan Khan, ... Bone marrow transplantation 54 (3), 353-367, 2019 | 125 | 2019 |
| Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category E Muchtar, A Dispenzieri, SK Kumar, RP Ketterling, D Dingli, MQ Lacy, ... Leukemia 31 (7), 1562-1569, 2017 | 122 | 2017 |
| A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ... Mayo Clinic Proceedings 94 (3), 472-483, 2019 | 115 | 2019 |
| Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center Y Wang, MA Tschautscher, KG Rabe, TG Call, JF Leis, SS Kenderian, ... Haematologica 105 (3), 765, 2020 | 95 | 2020 |
| Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy E Muchtar, FK Buadi, A Dispenzieri, MA Gertz Acta haematologica 135 (3), 172-190, 2016 | 88 | 2016 |
| Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis JP Abeykoon, S Zanwar, A Dispenzieri, MA Gertz, N Leung, T Kourelis, ... Leukemia 33 (2), 531-536, 2019 | 87 | 2019 |
| Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ... Leukemia 32 (10), 2240-2249, 2018 | 81 | 2018 |
| Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? E Muchtar, MA Gertz, SK Kumar, G Lin, B Boilson, A Clavell, MQ Lacy, ... Amyloid 25 (2), 86-92, 2018 | 79 | 2018 |
| Antiviral prophylaxis in haematological patients: systematic review and meta-analysis D Yahav, A Gafter-Gvili, E Muchtar, K Skalsky, G Kariv, M Yeshurun, ... European journal of cancer 45 (18), 3131-3148, 2009 | 79 | 2009 |
| Autologous stem cell transplant for multiple myeloma patients 70 years or older E Muchtar, D Dingli, S Kumar, FK Buadi, A Dispenzieri, SR Hayman, ... Bone marrow transplantation 51 (11), 1449-1455, 2016 | 75 | 2016 |
| Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study O Sneh-Arbib, A Shiferstein, N Dagan, S Fein, L Telem, E Muchtar, ... European journal of clinical microbiology & infectious diseases 32, 1511-1516, 2013 | 74 | 2013 |
| Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition E Muchtar, A Dispenzieri, MQ Lacy, FK Buadi, P Kapoor, SR Hayman, ... Annals of medicine 49 (7), 545-551, 2017 | 66 | 2017 |
| The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment E Muchtar, D Jevremovic, A Dispenzieri, D Dingli, FK Buadi, MQ Lacy, ... Blood, The Journal of the American Society of Hematology 129 (1), 82-87, 2017 | 64 | 2017 |
| Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment H Magen, E Muchtar Therapeutic Advances in Hematology 7 (4), 187-195, 2016 | 64 | 2016 |
| Systemic immunoglobulin light chain amyloidosis–associated myopathy: presentation, diagnostic pitfalls, and outcome E Muchtar, D Derudas, M Mauermann, T Liewluck, A Dispenzieri, ... Mayo Clinic Proceedings 91 (10), 1354-1361, 2016 | 62 | 2016 |
Angela DispenzieriMayo Clinic在 mayo.edu 的电子邮件经过验证
